Achaogen is discovering and developing life-saving antibiotics.

Synosia Therapeutics is a CNS focused company developing novel treatments for psychiatric and neurological disorders.

Euro Ventures, Inc. is an incubator company forming development stage start ups through acquisition of assets from European-based pharma companies.

Sebacia is developing novel technology to address a large unmet need in dermatology.

Semprae Laboratories, Inc. is a company founded by women and focused on women's sexuality.

Sentient is a seed stage start up company focused on developing products for outpatient interventional procedures.

Seredigm is focused on developing novel drugs that protect against tissue damage in a variety of acute or chronic medical conditions.

Spark Diagnostics is a diagnostics company utilizing next-gen sequencing technology to more efficiently and effectively diagnose disease.

(NASDAQ:CADX)

Cadence Pharmaceuticals is developing and commercializing pharmaceuticals to meet the needs of hospitalized patients.

Kythera is focused on science and innovation in aesthetic dermatology.

(NASDAQ:ALXA)

Alexza is a specialty pharmaceutical company developing fast onset medications.

Amira is an R&D Company focused on the development of novel therapies for respiratory and other inflammatory diseases.

Amphora will create the first comprehensive chemical genomics knowledge set, detailing the interactions of small drug molecules with a broad array of protein targets. The company plans to commercialize this knowledge set in a series of drug discovery alliances with pharmaceutical and biotech companies and to sell drug candidates that Amphora has internally developed.

Antipodean is a drug development company focused on a platform of mitochondria targeted antioxidants for several degenerative diseases.

Delivery of simple, accessible bio-molecule detection and analysis solutions to the life sciences market.

5AM Ventures is a seed-stage fund focused on creating and building biotech companies.

FivePrime accelerates drug discovery by rapidly isolating and assaying the world's largest collection of pharmaceutically relevant targets and therapeutics from the human genome.

(FLDM in registration)

Fluidigm has developed the biological and chemical equivalent of the integrated circuit called Integrated Fluidic Circuits (IFC's). IFC's incorporate tens of thousands of miniature channels, pumps and valves. IFC's integrate biological and chemical reactions on a massive scale.

(NASDAQ:GHDX)

Genomic Health gives cancer patients and physicians insight needed to help make quality treatment decisions. The first diagnostic assay developed by Genomic Health – Oncotype DX™ – is a breast cancer test that may assist treatment planning by quantifying the likelihood of distant breast cancer recurrence.

(NASDAQ:HLCS)

Helicos BioSciences Corporation is developing instruments for high-speed sequencing of DNA or RNA without amplification.

ISB Accelerator Corporation is building the next generation of life-enhancing biotechnology companies by providing world-class scientific and technical expertise, committed venture capital funding, state-of-the-art facilities and experienced biotechnology business management to accelerate the development of nascent leading-edge biotechnologies.

Natural language processing technology and services for medical coding and data analysis.

(NASDAQ:JAZZ)

Jazz Pharmaceuticals, founded by an executive team with outstanding experience and success in the pharmaceutical industry, will develop and market drugs serving the neurology and psychiatry markets.

Metabolex is an R&D based company focused on novel therapies for the treatment of diabetes and related metabolic disorders.

Groove BioPharma develops therapeutics using Minor Groove Binder Technology (MGB) to affect cellular processes involving microRNAs.

(NASDAQ:TSPT)

Transcept Pharmaceuticals is an oncology biopharmaceutical company committed to creating a world-class drug development and commercialization organization that addresses significant unmet medical needs.

(Sold to Merck)

NovaCardia is an emerging cardiovascular pharmaceutical company focused on the development and commercialization of novel clinical stage drug candidates.

(Sold to Affymetrix)

ParAllele is accelerating healthcare breakthroughs by providing comprehensive genetic discovery solutions to the life sciences research, pharmaceutical, and diagnostic sectors.

(PHRM : Sold to Celgene)

Pharmion is an emerging pharmaceutical company focused on marketing drugs that require specialized medical education and marketing programs. Founded by two highly experienced industry executives, the company's initial focus is on drugs currently marketed for the treatment of cancer and related diseases for markets in the US, as well as in Europe and other major international markets.

Phenomix is a biopharmaceutical company focused on dicovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets.

Pathwork Diagnostics is developing innovative molecular diagnostic tests for cancer.

APT Pharmaceuticals is developing inhaled therapies for severe lung disorders.

Okairos is using a best-in-class, proprietary genetic vaccine technology to develop vaccines for major unmet diseases, such as malaria, hepatitis C (HCV) and a universal influenza vaccine.

OpGen is developing a molecular biology system to automate rapid (2-hour) identification of infection-causing bacteria for deployment in the central microbiology lab.

(NASDAQ:TSRX)

Trius Therapeutics, Inc. is a biopharmaceutical company developing antibacterial drugs for the treatment of serious infections.

Vital Therapies has developed the first human cell artificial liver, trade-named ELAD (Extracoporeal Liver Assist Device).

(Australian Stock Exchange:IPD)

Impedimed offers an innovative technology for monitoring lymphedema following breast cancer surgery.

Quanticel is a biotechnology company that leverages unique insights in single cell biology and tumor heterogeneity to discover novel cancer drugs

(Sold to GlaxoSmithKline)

Reliant Pharmaceuticals is a specialty pharmaceutical company engaged in the acquisition, development and marketing of pharmaceutical products.

Saegis Pharmaceuticals is dedicated to developing new medicines that protect and improve memory and cognition.

(Sold to Cephalon)

Salmedix is focused on the development of clinical-stage drugs for the treatment of leukemias and lymphomas. The company has initiated human clinical trials for its first drug candidates, and is establishing a drug discovery to screen potential anticancer agents for a novel type of activity, which the company believes, will lead to a new strategy for fighting cancer.

(Sold to Takeda)

Syrrx is the technological leader in the field of structural proteomics. The company uses its proprietary technologies to generate protein structures, which are then used to rapidly discover new drugs.

CardioNow provides image management services for cardiology departments.

Cogent provides comprehensive hospitalist programs for acute care hospitals.

Collabrys provides outsourced, software-driven, full-service solutions that enable marketing professionals to launch new products, build brands, and increase consumer share.

(Acquired by Merge Healthcare)

Confirma sells CAD software tools for the management and analysis of breast MRI data.

RedBrick Health provides employers with an innovative technology and financing platform for achieving high levels of employee health engagement and reducing avoidable healthcare costs.

MedManage develops and deploys technology-based drug sampling solutions for pharmaceutical companies to accelerate prescription drug sales.

New Hope Bariatrics develops, markets, and operates centers of excellence for obesity surgery, providing outpatient surgery and related pre and post surgical care.

Skylight develops and operates hospital room interactive communication systems to provide hospital administrative and patient services.

Titan develops and operates ambulatory surgicenters.

Vantage develops and operates state-of-the-art radiation oncology centers.

(Acquired by Johnson & Johnson)

Acclarent, Inc. offers a novel system for "balloon sinuplasty" to treat sinus disease.

AcuFocus is developing a corneal implant to treat presbyopia (the need for reading glasses).

Calypso Medical Technologies is a Seattle-based, early-stage medical device company developing a novel method of localizing tumors to better guide radiation therapy.

Cameron Health is developing a novel Implantable Cardioverting Defibrillator (S-ICD) without intravenous leads.

Cellutions is developing minimally invasive devices for cosmetic procedures.

Glaukos is developing an implantable device to treat glaucoma.

GluMetrics, Inc. is a medical device company focused on bringing life-saving glucose monitoring products to the healthcare market.

Inogen develops and manufactures highly innovative, portable, lightweight oxygen concentrators for the home and ambulatory oxygen markets.

(NASDAQ:PODD)

Insulet offers a disposable insulin pump for the treatment of diabetes.

(NASDAQ:ILSE)

IntraLase develops and manufactures femtosecond lasers which create safer, more precise corneal flaps for improved laser vision correction surgery.

(Sold to Medicis)

Liposonix is developing a medical device to noninvasively and permanently remove unwanted fat from the body.

MitraLife is developing a medical device for the treatment of congestive heart failure. Acquired by ev3.

NDO Surgical develops, manufactures, and markets innovative endoscopic technologies for gastrointestinal disease.

(Acquired by Intuitive Surgical)

NeoGuide is developing advanced endoscopes and catheters for therapeutic and visualization procedures.

NeoVista is developing radiation delivery technology to treat age-related macular degeneration (AMD)

Neurotech Pharmaceuticals is pioneering encapsulated cell technology as a drug delivery platform for retinal degenerative diseases.

Nexis Vision is evaluating a variety of technologies to address important unmet patient needs in key ophthalmic markets.

Refractec develops and markets new products using radiofrequency technology for the treatment of farsightedness and presbyopia.

Intuity Medical is developing products that will enhance glucose monitoring for diabetic patients.

Novel device for treating lung diseases

Rox is developing devices for treatment of diseases of the respiratory system.

Fidelis Senor Care develops and operates specialized health plans for frail seniors.

Second Sight is developing a prosthetic retinal implant which will return functional vision to patients blinded from retinitis pigmentosa and age-related macular degeneration.

Sequent Medical is developing novel devices for the treatment of vascular disease.

Spiration is developing implantable surgical devices for the treatment of lung disease.

St. Francis Medical offers a surgical implant for the treatment of spinal stenosis, a common cause of back pain, particularly in older patients.

With a focus on inflammatory diseases, Flexion in-licenses clinically enabled drug candidates with high-value specialty potential and develops these to proof of concept (PoC) and beyond.

Tensys is developing non-invasive blood pressure monitors and disposable sensors.

(Acquired by Medtronic)

Ablation Frontiers is developing a catheter system to treat atrial fibrillation.

Fovioptics is developing a novel non-invasive glucose monitoring technology.

Celula is developing molecular diagnostics using advanced microfluidics technologies.

Ceterix is developing a new orthopedic suturing technology that is focused on improving ease-of-use and operative speed.

Transcend Medical is an opthalmic technology incubator.

ForSight New Co II is developing an implantable drug delivery device.

ForSight VISION4 is evaluating a variety of technologies to address important unmet patient needs in key ophthalmic markets.

ForSight Vision 5, Inc. is developing novel ocular drug delivery technologies.

Portaero, Inc. is developing a treatment for emphysema.

Benvenue is developing innovative spine-related technology.

NovaLign is developing a therapeutic device for long bone fracture fixation.

WaveTec Vision is developing ORange™, a novel wavefront measurement technology that provides on-demand, intraoperative information to the refractive cataract surgeon.

VLST Corp. has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases.

Homestead Clinical Corporation commercializes technologies that have broad utility in the development of novel diagnostic, prognostic, and theranostic tools.

Theraclone Sciences, Inc. is focused on developing novel human therapeutic antibodies for the treatment of infectious diseases.

Ambrx Inc. is a company working on a protein technology platform with a focus on protein engineering.

VerCo is a seed stage company focused on sourcing and offshore development of clinical stage oncology products.

(Sold to Bausch & Lomb)

Eyeonics has developed a proprietary presbyopic intraocular lens.

Leading industry provider of innovative 3-D technology solutions facilitating and improving the quality of orthodontic care.

Anza Therapeutics is developing therapeutic vaccines for infectious disease and cancer.

Advanced ICU care provides remote (telemedicine) patient care services, known as "virtual ICUs", for community hospital intensive care units (ICUs). The virtual ICU is a cost-efficient model for improving care and reducing mortality.

Anaphore is a protein therapeutics company which is developing improved biologic therapeutics using proprietary established platforms.

Immune Design Corp. is a biotechnology company focused on developing a broad platform of novel vaccines (both therapeutic and prophylactic) for the treatment of infectious disease.

Inception Sciences is a drug discovery incubator based on a proven team of drug developers. The company is translating biological insights into novel, first-in-class small molecule drugs for modifying diseases of aging.

LenSx Lasers is developing a next generation laser to improve cataract surgery safety and efficacy.

Rennovia is an early stage chemical development company working to produce specialty chemicals from renewable feedstock.

Kinestral Technologies is developing novel new chemistry applied to building materials for energy efficiency.

Novasys Medical is developing innovative therapies in women's health, and has recently launched its first product: the Renessa® System, a proprietary, non-surgical treatment for female stress urinary incontinence (SUI).

PhaseRx is developing a novel approach to intracellular delivery of macromolecules.

Respicardia, Inc. is developing an implantable medical device targeted at improving the outcomes of Congestive Heart Failure (CHF) by treating Central Sleep Apnea.

Lutonix, Inc. is developing drug coated balloon angioplasty technology for the treatment and prevention of coronary and peripheral artery stenosis caused by atherosclerosis.

Microfabrica, Inc is a leading developer of micro and millimeter-scale devices and micro machines used in a wide variety of micro-invasive medical device applications, as well as in applications in the electronics and defense industries.

Minerva is developing a medical device for treating excessive menstrual bleeding.

Alter-G is marketing its "G-Trainer" technology, a treadmill system that reduces the users' body weight/impact of running and thereby enhances physical rehabilitation from orthopedic or neurological injury.

Veracyte is a start-up company focused on molecular diagnostics.

AestheTec is developing autologous fat technologies for aesthetic and reconstructive markets.

ATI is developing an implantable neuromodulation system for patients suffering from migraines and other severe headaches.

Clovis Oncology is a newly formed company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets.

Intersection Medical is developing a cardiovascular monitoring system for patients with congestive heart failure.

Ocular Therapeutix has a novel PEG hydrogel platform technology focused on ocular sealant, wound closure, and drug delivery.